| Kristina Marie Trout, AUD | |
|
1110 W Main Cross St, Findlay, OH 45840-2423 | |
| (419) 424-1393 | |
| Not Available |
| Full Name | Kristina Marie Trout |
|---|---|
| Gender | Female |
| Speciality | Qualified Audiologist |
| Experience | 18 Years |
| Location | 1110 W Main Cross St, Findlay, Ohio |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1629151543 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 231H00000X | Audiologist | (* (Not Available)) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Specialty Physicians Of Blanchard Valley Llc | 2668547613 | 102 |
News Archive
Dandruff sufferers now have a non-toxic product to treat the condition, says a researcher at Georgia Health Sciences University.
A study presented today at the IASLC 2021 World Conference on Lung Cancer suggests how oncology practices in the United States changed after 2018, when durvalumab became available for patients with unresectable Stage III non-small cell lung cancer.
The "Work Design for Health" framework—developed by Harvard T.H. Chan School of Public Health and MIT Sloan School of Management researchers—maps how to create work environments that foster worker health and well-being.
Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced positive top-line results from its double-blinded placebo controlled Phase 2b study of PRX302 (study name: TRIUMPH) in patients with moderate to severe benign prostatic hyperplasia (BPH), a painful and bothersome urological condition that affects more than 50 million men worldwide.
› Verified 7 days ago
| Provider Name | Specialty Physicians Of Blanchard Valley Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1689835415 PECOS PAC ID: 2668547613 Enrollment ID: O20080826000542 |
News Archive
Dandruff sufferers now have a non-toxic product to treat the condition, says a researcher at Georgia Health Sciences University.
A study presented today at the IASLC 2021 World Conference on Lung Cancer suggests how oncology practices in the United States changed after 2018, when durvalumab became available for patients with unresectable Stage III non-small cell lung cancer.
The "Work Design for Health" framework—developed by Harvard T.H. Chan School of Public Health and MIT Sloan School of Management researchers—maps how to create work environments that foster worker health and well-being.
Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced positive top-line results from its double-blinded placebo controlled Phase 2b study of PRX302 (study name: TRIUMPH) in patients with moderate to severe benign prostatic hyperplasia (BPH), a painful and bothersome urological condition that affects more than 50 million men worldwide.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kristina Marie Trout, AUD 1110 W Main Cross St, Findlay, OH 45840-2423 Ph: (419) 424-1393 | Kristina Marie Trout, AUD 1110 W Main Cross St, Findlay, OH 45840-2423 Ph: (419) 424-1393 |
News Archive
Dandruff sufferers now have a non-toxic product to treat the condition, says a researcher at Georgia Health Sciences University.
A study presented today at the IASLC 2021 World Conference on Lung Cancer suggests how oncology practices in the United States changed after 2018, when durvalumab became available for patients with unresectable Stage III non-small cell lung cancer.
The "Work Design for Health" framework—developed by Harvard T.H. Chan School of Public Health and MIT Sloan School of Management researchers—maps how to create work environments that foster worker health and well-being.
Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced positive top-line results from its double-blinded placebo controlled Phase 2b study of PRX302 (study name: TRIUMPH) in patients with moderate to severe benign prostatic hyperplasia (BPH), a painful and bothersome urological condition that affects more than 50 million men worldwide.
› Verified 7 days ago
Dr. Michael Anthony Webb, AUD Audiologist Medicare: Medicare Enrolled Practice Location: 540 S Main St, Suite B, Findlay, OH 45840 Phone: 419-425-1394 Fax: 419-425-8010 | |
Bethany Rachel Holland, AUD Audiologist Medicare: Accepting Medicare Assignments Practice Location: 1110 W Main Cross St Ste G, Findlay, OH 45840 Phone: 419-423-5492 | |
Alyssa Jo Martin, A.UD. Audiologist Medicare: Accepting Medicare Assignments Practice Location: 1110 W Main Cross St, Findlay, OH 45840 Phone: 419-432-5492 | |
Susan Marie Stamm, M.S.CCC/A Audiologist Medicare: Not Enrolled in Medicare Practice Location: 1110 W Main Cross St, Findlay, OH 45840 Phone: 419-424-1393 Fax: 419-424-3424 | |
Jennifer L Bournique, AU. D. Audiologist Medicare: Not Enrolled in Medicare Practice Location: 1110 W Main Cross St, Findlay, OH 45840 Phone: 419-424-1393 Fax: 419-424-3424 | |
Precise Audiology, Incorporated Audiologist Medicare: Medicare Enrolled Practice Location: 540 S Main St, Suite B, Findlay, OH 45840 Phone: 419-425-1394 Fax: 419-425-8010 |